anti-CCR6 monoclonal antibodies (Sorrento Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CCR6 monoclonal antibodies (Sorrento Therapeutics)
Drug Alias NameSTI-B100X
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionC-C chemokine receptor type 6 inhibitors
TargetsC-C chemokine receptor type 6
Therapy Area/IndicationsInflammationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSorrento Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsInflammationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A